Mor Lab

Publications

2024

  • Gartshteyn Y, Geraldino-Pardilla L, Khalili L, Bukhari S, Lerrer S, Winchester RJ, Askanase AD, Mor A. SAP-expressing T peripheral helper cells identify systemic lupus erythematosus patients with lupus nephritis. Front Immunol. 2024 Mar 14;15:1327437. 

  • Hu X, Bukhari SM, Tymm C, Adam K, Lerrer S, Henick BS, Winchester RJ, Mor A. Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity. J Immunother Cancer. 2024 Mar 21;12(3):e008482. 

  • Philips EA, Liu J, Kvalvaag A, Mørch AM, Tocheva AS, Ng C, Liang H, Ahearn IM, Pan R, Luo CC, Leithner A, Qin Z, Zhou Y, Garcia-España A, Mor A, Littman DR, Dustin ML, Wang J, Kong XP. Transmembrane domain-driven PD-1 dimers mediate T cell inhibition. Sci Immunol. 2024 Mar 8;9(93):eade6256. 

  • Straube J, Bukhari S, Lerrer S, Winchester RJ, Gartshteyn Y, Henick BS, Dragovich MA, Mor A. PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis. Arthritis Res Ther. 2024 Jan 22;26(1):32. .  

2023

  • Hao LY, Lerrer S, Song R, Goeckeritz M, Hu X, Mor A. Exclusion of PD-1 from the immune synapse: a novel strategy to modulate T cell function. bioRxiv [Preprint]. 2023 Nov 17:2023.11.16.566907. 

  • Bukhari S, Henick BS, Winchester RJ, Lerrer S, Adam K, Gartshteyn Y, Maniar R, Lin Z, Khodadadi-Jamayran A, Tsirigos A, Salvatore MM, Lagos GG, Reiner SL, Dallos MC, Mathew M, Rizvi NA, Mor A. Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Rep Med. 2023 Jan 17;4(1):100868. 

2022

  • Strazza M, Moore EK, Adam K, Azoulay-Alfaguter I, Mor A. Neutralization of the adaptor protein PAG by monoclonal antibody limits murine tumor growth. Mol Ther Methods Clin Dev 2022; 27: 380-390.

  • Gartshteyn Y, Askanase AD, Song R, Bukhari S, Dragovich M, Adam K, Mor A. SLAMF6 compartmentalization enhances T cell functions. Life Sci Alliance 2022; 6: e202201533.

  • Moore EK, Strazza M, Mor A. Combination approaches to target PD-1 signaling in cancer. Front Immunol 2022; 13: 927265.  

  • Adam K, Mor A. Immunohistochemistry of immune cells and cells bound to in vivo administered antibodies in liver, lung, pancreas, and colon of B6/lpr mice. Bio Protoc 2022; 12: e4468.

2021

  • Mor A, Strazza M. Bridging the gap: connecting the mechanisms of immune related adverse events and autoimmunity through PD-1. Front Cell Dev Biol 2021;
  • Gartshteyn Y, Mor A, Shimbo D, Khalili L, Kapoor T, Geraldino-Pardilla L, Alexander RV, Conklin J, Dervieux T, Askanase AD. Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in systemic lupus erythematosus. Clin Immunol 2021; May 10;108755.
  • Lerrer S, Bukhari SM, Adam K, Mor A. PD-1-stimulated T cell subsets are transcriptionally and functionally distinct. iScience 2021; 24: 103020.
  • Strazza M, Azoulay-Alfaguter I, Peled M, Adam K, Mor A. Transmembrane adaptor protein PAG is a novel mediator of PD-1 inhibitory signaling in T cells. Comms Bio 2021; 4: 672.
  • Strazza M, Bukhari SM, Tocheva AS, Mor A. PD-1 induced proliferating T cells exhibit a distinct transcriptional signature. Immunology 2021;
  • Peled M, Adam K, Mor A. VRK2 inhibition synergizes with PD-1 blockade to improve T cell responses. Immunol Lett 2021; 2478: 45-6.
  • Peled M, Adam K, Mor A. Data on the Identification of VRK2 as a mediator of PD-1 function. Data in Brief 2021; 37: 107168.
  • Peled M, Bar-Lev TH, Bar J, Kamer I, Ofek E, Mor A, Onn A. MANF, a potential immunomodulator, is an activator of tumor cells through ER calcium depletion. PLoS One 2021; Apr 23;16(4):e0250178.
  • Adam K, Iuga A, Tocheva AS, Mor A. A novel mouse model for checkpoint inhibitor-induced adverse events. PLoS One 2021; 16:e0246168.
  • Strazza M, Straube J, Lerrer S, Adam K, Sandigursky S, Ueberheide B, Mor A. SHP2 targets ITK downstream of PD-1 to inhibit T cell function. Inflammation 2021; doi: 10.1007/s10753-021-01437-8.
  • Gartshteyn Y, Askanase AD, Mor A. SLAM Associated Protein signaling in T cells: tilting the balance toward autoimmunity. Front Immunol 2021; doi: 10.3389/fimmu.2021.654839.

2020

  • Tocheva AS, Peled M, Strazza M, Adam K, Lerrer S, Nayak S, Azoulay-Alfaguter I, Foster C, Philips EA, Neel BG, Ueberheide B, Mor A. Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions. J Biol Chem 2020; 295: 18036-18050.
  • Philips EA, Garcia-España A, Tocheva AS, Ahearn IM, Adam KR, Pan R, Mor A, Kong XP. The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals. J Biol Chem 2020; 295: 4372-4380.
  • Strazza M, Adam K, Smrcka AV, Lerrer S, Mor A. PLCε1 suppresses tumor growth by regulating murine T cell mobilization. Clin Exp Immunol 2020; 1: 53-60.
  • Sandigursky S, Philips MR, Mor A. SAP interacts with CD28 to inhibit PD-1 signaling in T lymphocytes. Clin Immunol 2020; 108485.
  • Tocheva A, Lerrer S, Mor A. In vitro assays to study PD-1 biology in human T cells. Curr Proto Immunol 2020; 130;e103.
  • Azoulay-Alfaguter I, Mor A. Isolation and characterization of T lymphocyte exosomes using mass spectrometry. Methods Mol Biol 2020; 2184: 91-102.
  • Strazza M, Mor A. The complexity of targeting chemokines to promote a tumor immune response. Inflammation 2020; 43: 1201-1208.
  • Strazza M, Mor A. Chemokines and cancer - friends or foes? Mucosal Immunology 2020; 4: 118-20.

2019

  • Dragovich MA, Adam K, Strazza M, Tocheva AS, Peled M, Mor A. SLAMF6 clustering is required to augment T cell activation. PLoS One 2019; 2006: 131-140.
  • Lerrer S, Mor A. Implementing the shared epitope model through PD-1 blockade. Tran Cancer Res 2019; doi: 10.21037/tcr.2019.07.43.

2018

  • Peled M, Strazza M, Mor A. Co-immunoprecipitation assay for studying functional interactions between receptors and enzymes. J Vis Exp 2018; 139: 58433.
  • Azoulay-Alfaguter I, Mor A. Proteomic analysis of human T cell-derived exosomes reveals differential RAS/MAPK signaling. Eur J Immunol. 2018; 48: 1915-1917.
  • Peled M, Verga IE, Ueberheide M, Mor A. EFHD2 is a novel regulator of PD-1 function. J Immunol 2018; 48: 2824-31.
  • Peled M, Tocheva A, Sandigursky S, Nayak S, Strazza M, Azulay-Alfaguter I, Philips EA, Askenazi M, Pelzek A, Neel B, Nichols K, Ueberheide B, Mor A. Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor. Proc Natl Acad Sci 2018; 115: 468-77.
  • Sandigursky S, Mor A. Immune related adverse events in cancer patients treated with immune checkpoint inhibitors. Current Rheumatology 2018; 20: 65.
  • Dragovich M, Mor A. The SLAM family receptors: potential therapeutic targets for inflammatory and autoimmune diseases. Autoimm Rev 2018; 17: 674-82.
  • Silverman GJ, Azzouz DF, Mor A. Immune checkpoint inhibitors and the union of bugs against cancer. Kidney Int 2018; 93: 1030-1032.

2017

  • Shefler I, Salamon P, Levi-Schaffer F, Mor A, Hershko AY, Mekori YA. MicroRNA-4443 regulates mast cell activation by T cell-derived microvesicles. J Allergy Clin Immunol 2017; 6749: 31278-2.
  • Azoulay-Alfaguter I, Strazza M, Peled M, Novak H, Muller J, Dustin ML, Mor A. The tyrosine phosphatase SHP-1 promotes T cell adhesion by activating the adaptor protein CrkII in the immunological synapse. Sci Signal 2017; 10:eaal2880.
  • Strazza M, Azoulay-Alfaguter I, Peled M, Smrcka AV, Skolnik EY, Srivastava S, Mor A. PLCε1 mediates cellular adhesion downstream of SDF-1α in T cells. Proc Natl Acad Sci 2017; 114: 2693-8.
  • Strazza M, Mor A. Consider the chemokines: a review of the interplay between chemokines and T cell subset function. Discov Med 2017; 24: 31-39.
  • Tocheva AS, Mor A. Checkpoint inhibitors: applications for autoimmunity. Curr Allergy Asthma Rep 2017; 17: 72.
  • Sandigursky S, Silverman GJ, Mor A. Targeting the programmed cell death-1 pathway in rheumatoid arthritis. Autoimm Rev 2017; 16: 767-773.
  • Shah N, Sandigursky S, Mor A. The potential role of inhibitory receptors in the treatment of psoriasis and psoriatic arthritis.  Bull Hosp Jt Dis 2017; 75: 155-163.

2016

  • Strazza M, Azoulay-Alfaguter I, Peled M, Mor A. Assay of adhesion under shear stress for the study of T lymphocyte adhesion. J Vis Exp 2016; 112.

2015

  • Su W, Wynne J, Pinheiro EM, Strazza M, Mor A, Montenont E, Berger J, Paul DS, Bergmeier W, Gertler FB, Philips MR. Rap1 and its effector Riam are required for lymphocyte trafficking. Blood 2015; 126: 2695-703.
  • Peled M, Strazza M, Azoulay-Alfaguter I, Mor A. Analysis of PD-1 in patients with psoriatic arthritis. Inflammation 2015; 38: 1573-9
  • Strazza M, Azoulay-Alfaguter I, Dun B, Baquero-Buitrago J, Mor A. CD28 inhibits T cell adhesion by recruiting CAPRI to the plasma membrane. J Immunol 2015; 194: 2871-7.
  • Azoulay I, Strazza M, Peodeem A, Mor A. The coreceptor PD-1 inhibits T cell adhesion by regulating Rap1. J Allergy Clin Immunol 2015; 135: 564-7.
  • Strazza M, Azoulay-Alfaguter I, Silverman GJ, Mor A. T cell chemokine receptor patterns as pathogenic signatures in autoimmunity. Discov Med 2015; 19: 117-25.

2014

  • Joseph KA, Luu X, Mor A. Granulomatous mastitis: A New York public hospital experience. Ann Surg Oncol 2014; 21: 4159-63.

  • Strazza M, Azoulay-Alfaguter I, Pedoeem A, Mor A. Static adhesion assay for the study of integrin activation in T lymphocytes. J Vis Exp 2014; 88.

  • Kloog Y, Mor A. Cytotoxic T lymphocyte antigen 4 receptor signaling for lymphocyte adhesion is mediated by C3G and Rap1. Mol Cell Biol 2014; 34: 978-88.

  • Aizman E, Blacher E, Ben-Moshe O, Kogan T, Kloog Y, Mor A. Therapeutic effect of farnesylthiosalicylic acid on adjuvant-induced arthritis through suppressed release of inflammatory cytokines. Clin Exp Immunol 2014; 175: 454-8.

  • Azoulay-Alfaguter I, Strazza M, Mor A. Chaperone-mediated specificity in Ras and Rap signaling. Crit Rev Biochem Mol Biol 2014; 9: 1-9

  • Tapia M, Mor A. Lymphocyte adhesion and autoimmunity. Bull Hosp Jt Dis 2014; 72: 148-53.

  • Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 2014; 153: 145-52.

2013

  • Mor A, Aizman E, Chapman J, Kloog Y. Immunomodulatory properties of farnesoids: The new steroids? Curr Med Chem 2013; 20: 1218-24.
  • Kloog Y, Haklai R, Elad-Sfadia G, Mor A. Ras chaperons: targets for cancer and immune therapy. Enzymes 2013; 33: 267-89.